Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum complement in chronic liver disease.

B J Potter, A M Trueman, E A Jones

    Gut
    |June 1, 1973
    PubMed
    Summary
    This summary is machine-generated.

    Serum complement levels (CH50, C3, C4) differ across chronic liver diseases. Primary biliary cirrhosis shows elevated CH50 and C3, unlike other conditions, suggesting distinct immune profiles in liver disease patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Increases in the enzyme activity of mouse mammary explants induced by prolactin.

    The Journal of endocrinology·2025
    Same author

    Hospitalization and hospital mortality rates during the first and second waves of the COVID-19 pandemic in Quebec: interrupted time series and decomposition analysis.

    Public health·2023
    Same author

    Predictors and impact of postoperative atrial fibrillation following thoracic surgery: a state-of-the-art review.

    Anaesthesia·2023
    Same author

    Obstetric haemorrhage and risk of cardiovascular disease after three decades: a population-based cohort study.

    BJOG : an international journal of obstetrics and gynaecology·2020
    Same author

    The role of receptor MAS in microglia-driven retinal vascular development.

    Angiogenesis·2019
    Same author

    Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis.

    The British journal of dermatology·2019
    Same journal

    Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.

    Gut·2026
    Same journal

    Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.

    Gut·2026
    Same journal

    USP20 promotes CD8<sup>+</sup> T cell exhaustion and impairs KRAS<sup>G12D</sup> inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.

    Gut·2026
    Same journal

    CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease.

    Gut·2026
    Same journal

    <i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials.

    Gut·2026
    Same journal

    Correction: Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.

    Gut·2026
    See all related articles

    Area of Science:

    • Immunology
    • Hepatology
    • Biochemistry

    Background:

    • Chronic liver diseases involve immune dysregulation.
    • Complement system components (C3, C4) and activity (CH50) are crucial in immunity.
    • Distinct patterns of complement alteration may differentiate liver disease subtypes.

    Purpose of the Study:

    • To investigate serum complement activity (CH50) and component levels (C3, C4) in patients with chronic liver disease.
    • To compare complement profiles across different chronic liver diseases, including primary biliary cirrhosis, chronic active hepatitis, and cryptogenic cirrhosis.
    • To explore the relationship between complement changes and cholestasis in liver disease.

    Main Methods:

    • Measurement of total serum haemolytic complement activity (CH50).

    Related Experiment Videos

  • Quantification of serum concentrations of complement components C3 and C4.
  • Comparative analysis of complement parameters in control subjects, chronic liver disease patients, and patients with biliary tract obstruction.

    • Main Results:

    • Reduced mean C4 concentration observed in all studied chronic liver diseases.
    • Elevated CH50 and C3 in compensated primary biliary cirrhosis, potentially linked to cholestasis.
    • Decreased CH50 and C3 in cryptogenic cirrhosis, especially with ascites; normal levels in non-cirrhotic chronic active hepatitis.
    • Significant correlation found between CH50 and C3 in chronic liver disease patients.

    Conclusions:

    • Distinct serum complement profiles characterize different chronic liver diseases, despite their association with immune disturbances.
    • Elevated CH50 and C3 in primary biliary cirrhosis may be partly attributed to concurrent cholestasis.
    • Complement analysis provides a means to differentiate between primary biliary cirrhosis, chronic active hepatitis, and cryptogenic cirrhosis.